Inozyme Pharma. has filed a patent for compositions and methods to treat allograft vasculopathy, Moyamoya Diseases, and Moyamoya Syndrome by administering ENPP1 or ENPP3 agents. The patent claims have been canceled. GlobalData’s report on Inozyme Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Inozyme Pharma Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Inozyme Pharma, Adeno-associated virus vectors was a key innovation area identified from patents. Inozyme Pharma's grant share as of January 2024 was 7%. Grant share is based on the ratio of number of grants to total number of patents.

Treating allograft vasculopathy, moyamoya diseases, inhibiting intimal proliferation

Source: United States Patent and Trademark Office (USPTO). Credit: Inozyme Pharma Inc

A patent application (Publication Number: US20240016951A1) discloses a method for treating Moyamoya disease by administering an ENPP1 agent to a subject at risk or afflicted with the condition. The ENPP1 agent can include an ENPP1 polypeptide, a nucleic acid encoding the polypeptide, or a viral vector containing the nucleic acid. Various embodiments specify the composition of the ENPP1 polypeptide, including specific amino acid sequences and the addition of heterologous proteins to enhance its effectiveness. The method aims to inhibit cerebral vascular occlusion and unwanted vascular smooth muscle cell proliferation in Moyamoya disease patients, particularly those with specific genetic mutations or experiencing related complications.

Additionally, the patent application describes the use of ENPP1 agents in preventing allograft vasculopathy in subjects with transplanted organs and reducing vascular smooth muscle cell proliferation around arterio-venous dialysis shunt sites. The administration of ENPP1 agents, either before, during, or after surgical interventions, is proposed to mitigate these conditions. The ENPP1 agent formulations may include various components such as heterologous proteins to improve their pharmacokinetic properties. Overall, the disclosed methods offer potential therapeutic strategies for addressing vascular complications associated with Moyamoya disease, organ transplantation, and dialysis procedures, highlighting the versatility and applicability of ENPP1 agents in diverse clinical settings.

To know more about GlobalData’s detailed insights on Inozyme Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies